Development of Extended-Release Formulations Containing Cyclobenzaprine Based on Physiologically Based...

Area of Science:

• Pharmacokinetics and Drug Delivery
• Biopharmaceutics and Pharmaceutical Technology
• Computational Modeling in Drug Development

Background:

• Physiologically Based Biopharmaceutics Modeling (PBBM) and bioequivalence safe space are established for immediate-release products.
• Application of these advanced modeling techniques to extended-release (ER) formulations remains less explored.
• Developing ER formulations requires robust strategies to ensure in vivo performance and bioequivalence.

Purpose of the Study:

• To develop extended-release (ER) cyclobenzaprine formulations using PBBM and bioequivalence safe space.
• To evaluate the in vitro dissolution profiles of novel ER formulations against a reference product.
• To virtually assess the bioequivalence of developed ER formulations through PBBM predictions.

Main Methods:

• Preparation of four ER cyclobenzaprine formulations (F1-F3 mini-tablets, F4 tablet).
• In vitro dissolution testing of all formulations and the reference drug product.
• Establishment of a bioequivalence safe space based on reference product dissolution kinetics (first-order model).
• Setup and evaluation of a PBBM to predict in vivo performance.
• Virtual bioequivalence studies using PBBM predictions.

Main Results:

• The bioequivalence safe space was defined as ±25% to +75% of reference product k1 and Tlag values.
• ER mini-tablet formulation F2 exhibited dissolution profiles within the calculated safe space.
• Formulation F2 achieved virtual bioequivalence approval in 10 out of 10 simulated crossover trials.
• Despite failing the traditional f2 test, formulation F2 demonstrated virtual bioequivalence.

Conclusions:

• PBBM and bioequivalence safe space are effective tools for developing ER drug products.
• An ER mini-tablet formulation (F2) was successfully developed to be virtually bioequivalent to the reference product.
• These modeling approaches offer a powerful strategy for ER formulation development, potentially reducing the need for extensive in vivo testing.